Brello Tirzepatide: Dual-Agonist Routing, Evidence, and Cost

This review appears in the PlexusDx Education Hub, our resource for evidence-based coverage of GLP-1 therapies, weight-management protocols, and the genetics beneath them. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Brello or its parent company, and no affiliate links or compensation are involved.

Tirzepatide differs from single-target GLP-1 drugs, so "Brello tirzepatide" deserves its own explanation: how the program prescribes and dispenses it, what the trials showed, and what a course costs. This review covers all three and adds the genetic context a telehealth intake omits. Fair-balance, as of April 2026.

Tirzepatide: the dual-agonist difference

Tirzepatide is a GIP/GLP-1 dual agonist — it engages two receptor pathways rather than the single GLP-1 target of drugs like semaglutide, liraglutide, and dulaglutide. It is available as FDA-approved branded products and, separately, as compounded formulations from state-licensed 503A pharmacies. Brello (Brello Health) runs a telehealth-plus-compounded-pharmacy model; its specific tirzepatide offering is detailed on its own site.

Branded vs. compounded tirzepatide routing

Depending on eligibility and program design, a tirzepatide prescription from a telehealth operator may route to a retail pharmacy for an FDA-approved brand or to a 503A compounding pharmacy for a compounded version. The two follow different regulatory pathways; compounded tirzepatide is not an FDA-approved finished product. Confirm which route Brello uses on its own website before enrolling.

SURMOUNT and the evidence base

Tirzepatide's weight-management evidence comes largely from the SURMOUNT program (The New England Journal of Medicine, 2022), with SURMOUNT-OSA (NEJM 2024) examining obstructive sleep apnea. Semaglutide's comparison point is the STEP program (NEJM 2021). Trial populations and endpoints differ across these programs, and individual outcomes vary.

What a tirzepatide program costs

Branded versus compounded tirzepatide is the dominant cost variable. Brello publishes pricing on its own site, and totals move with product, subscription tier, and dispensing pathway. The broader telehealth GLP-1 market runs roughly $200 to $700 or more per month as of April 2026, with wide variance. Verify Brello's current pricing directly — numbers change often.

The genetics behind tirzepatide's pathways

Because tirzepatide works through more than one receptor pathway, the genetic terrain underneath it matters. Variants in FTO (fat-mass and obesity-associated), GLP1R (the GLP-1 receptor gene central to tirzepatide's GLP-1 arm), MC4R (a satiety-linked melanocortin receptor), and TCF7L2 (a glucose-homeostasis transcription factor) map your baseline metabolic biology. They are pathway-level markers — not response predictors — describing the biology a clinician prescribes into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The differentiator is what comes first: the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — FTO, MC4R, and TCF7L2 included — before a protocol begins. That is the test before you invest approach.

Not affiliated: PlexusDx is not affiliated with Brello and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: GLP 1 Drugs, GLP 1 Receptor Agonist, GLP 1 Hormone, What Is GLP 1.

Disclaimer: This article is educational. PlexusDx is not affiliated with Brello and has no commercial relationship with the companies reviewed; it offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

See the PlexusDx approach to tirzepatide: review the Weight Management Protocols, or begin with the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

Does Brello prescribe tirzepatide?

Brello operates a telehealth-plus-compounded-pharmacy model, so a clinician may prescribe tirzepatide as an FDA-approved brand product through a retail pharmacy or as a compounded formulation through a 503A pharmacy. Which route applies depends on eligibility and program design; confirm current options on Brello's own website.

What makes tirzepatide different from semaglutide?

Tirzepatide is a GIP/GLP-1 dual agonist, engaging two receptor pathways, while semaglutide is a single-target GLP-1 receptor agonist. Their evidence comes from different trial programs — SURMOUNT for tirzepatide and STEP for semaglutide — with differing populations and endpoints, and outcomes vary by individual.

Is compounded tirzepatide legitimate?

Compounded tirzepatide is prepared for individual patients by state-licensed 503A compounding pharmacies under a prescription. It is a regulated pathway distinct from FDA-approved brand manufacturing and is not an FDA-approved finished product. A credible program is transparent about which pharmacies fill its prescriptions.

How does PlexusDx compare to Brello for tirzepatide?

PlexusDx offers tirzepatide through its Weight Management Protocols and pairs it with the Precision Peptide Genetic Test. The distinction is the genetic layer delivered with the medication — pathway-level context most telehealth-only programs like Brello do not bundle with a tirzepatide prescription.

Keep reading in the PlexusDx Education Hub. Browse all Peptides & GLP-1 education